Years of sorafenib investigation in advanced non-small cell lung cancer: Is there a 'NExUS' linking an unsuccessful treatment and a potentially active one?

Journal of Thoracic Disease

Volumn 4, Issue 6, 2012, Pages 635-638

  Metro, Giulio ^a   Minotti, Vincenzo ^a   Crinò, Lucio ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; K RAS PROTEIN; SORAFENIB;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CELL CYCLE ARREST; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

EID: 84873628825     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.10.06     Document Type: Review

References (24)

1. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 1835-42.
2. Paz-Ares L.G., Biesma B, Heigener D., et al. Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2012; 30: 3084-92.
3. Molina JR., Dy GK, Foster N.R., et al. A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. J Clin Oncol 2011; 29:abstr 7513.
4. Blumenschein GR Jr, Gatzemeier U, Fossella F., et al Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 4274-80.
5. Wakelee HA, Lee JW, Hanna N.H., et al. A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43-9006) in Previously Treated Non-Small-Cell Lung Cancer Patients: Eastern Cooperative Oncology Group Study E2501. J Thorac Oncol 2012; 7: 1574-82.
6. Paz-Ares L., Hirsh V, Zhang L., et al. Monotherapy administration of sorafenib in patients with non-small cell lung cancer: phase III, randomized, double-blind, placebo-controlled MISSION trial. Ann Oncol 2012; 23:abstr33.
7. Davies AM, Ho C, Lara PN Jr, et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 2006; 7: 385-8.
8. Takezawa K, Okamoto I, Yonesaka K., et al. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res 2009; 69: 6515-21.
9. Sequist LV, Heist RS, Shaw A.T., et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011; 22: 2616-24.
10. Smit EF, Dingemans AM, Thunnissen F.B., et al. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. J Tnorac Oncol 2010; 5: 719-20.
11. Presented at: the 2012 AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and Personalized Medicine; Jan 8-11, 2012; San Diego#PR5.
12. Kelly RJ, Rajan A, Force J., et al. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res 2011; 17: 1190-9.
13. Kim ES, Herbst RS, Wistuba I.I., et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011; 1: 44-53.
14. Mok TSK, Paz-Ares L, Wu Y.L., et al. Association between tumor EGFR and KRAS mutation status and clinical outcomes in NSCLC patients randomized to sorafenib plus best supportive care (BSC) or BSC alone: Subanalysis of the phase III MISSION trial. Ann Oncol 2012; 23:abstr 9.
15. Lind JS, Dingemans AM, Groen H.J., et al. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res 2010; 16: 3078-87.
16. Spigel DR, Burris HA 3rd, Greco FA, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 2582-9.
17. Mao C, Qiu LX, Liao R.Y., et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010; 69: 272-8.
18. Janne PA, Shaw AT, Pereira J.R., et al. Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30:abstr 7503.
19. Metro G, Crinò L. Advances on EGFR mutation for lung cancer. Transi Lung Cancer Res 2012; 1: 5-13.
20. Janjigian YY, Smit EF, Horn L, et al. Activity of Afatinib/Cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors. Ann Oncol 2012; 23:abstr 1227.
21. Thomas M, Reuss A, Fischer J.R., et al. Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2011; 29:abstr 7504.
22. Morgillo F, Cascone T, D'Aiuto E, et al. Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. Br J Cancer 2011; 105: 382-92.
23. Yuen JS, Sim MY, Sim H.G., et al. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma. Int J Oncol 2012; 41: 712-20.
24. Koh YW, Shah MH, Agarwal K, et al. Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. Endocr Relat Cancer 2012; 19: 29-38.